ProACT eftergodkendelsesundersøgelse
Undersøgelse efter godkendelse af ProACT™ justerbar kontinensterapi til mænd
The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Matt Kelly, PhD
- Telefonnummer: 6124698882
- E-mail: usmtk@coloplast.com
Undersøgelse Kontakt Backup
- Navn: Lisa DRAPER
- E-mail: usldr@coloplast.com
Studiesteder
-
-
California
-
Los Angeles, California, Forenede Stater, 90033
- Rekruttering
- University of Southern California
-
Kontakt:
- Julissa Morales
- E-mail: julissa.morales@med.usc.edu
-
Ledende efterforsker:
- Jeffrey Loh-Doyle, MD
-
Santa Barbara, California, Forenede Stater, 93110
- Rekruttering
- Sutter Health
-
Kontakt:
- Morgan Caldwell-Holden
- E-mail: morgan.caldwell-holden@sutterhealth.org
-
Kontakt:
- Megan Martinez
- E-mail: megan.martinez@sutterhealth.org
-
Ledende efterforsker:
- Scott Tobis, MD
-
-
Colorado
-
Denver, Colorado, Forenede Stater, 80045
- Rekruttering
- University of Colorado
-
Kontakt:
- Andrea Pina
- E-mail: andrea.pinalimones@cuanschutz.edu
-
Ledende efterforsker:
- Brian Flynn, MD
-
Underforsker:
- Nate Coddington, MD
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32610
- Rekruttering
- University of Florida
-
Kontakt:
- John Marks, DHSc, CCRP
- Telefonnummer: 352-273-5618
- E-mail: John.Marks@urology.ufl.edu
-
Ledende efterforsker:
- Lawrence Yeung, MD
-
Hialeah, Florida, Forenede Stater, 33016
- Rekruttering
- Urological Research Network Corp
-
Ledende efterforsker:
- Edward Gheiler, MD
-
Kontakt:
- Isabel Lopez
- E-mail: isabel@besturology.net
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Emory University
-
Ledende efterforsker:
- Lindsey Hartsell, MD
-
Kontakt:
- Nahir Imtiaz
- E-mail: sbimtia@emory.edu
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66103
- Rekruttering
- University of Kansas Medical Center
-
Kontakt:
- Kirk Redger, MD
- Telefonnummer: 913-588-1227
- E-mail: kredger@kumc.edu
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Rekruttering
- University of Michigan
-
Kontakt:
- Nailah Henry
- E-mail: hnailah@med.umich.edu
-
Ledende efterforsker:
- Bahaa Malaeb, MD
-
-
Minnesota
-
Saint Cloud, Minnesota, Forenede Stater, 56303
- Rekruttering
- CentraCare- St. Cloud
-
Kontakt:
- Andrew Windsperger, MD
- Telefonnummer: 320-229-4547
- E-mail: andrew.windsperger@centracare.com
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68124
- Rekruttering
- CHI Health Research
-
Ledende efterforsker:
- Michael Feloney, MD
-
Kontakt:
- Jan Mitchell
- E-mail: jan.mitchell@commonspirit.org
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forenede Stater, 18103
- Rekruttering
- Lehigh Valley Health Network
-
Kontakt:
- Megan McGonagle, MSN, RN, PCCN
- E-mail: Megan.mcgonagle@jefferson.edu
-
Ledende efterforsker:
- Matthew Loecher, MD
-
Pittsburgh, Pennsylvania, Forenede Stater, 15212
- Rekruttering
- Allegheny Health Network
-
Kontakt:
- Rachel Reading
- E-mail: rachel.reading@ahn.org
-
Kontakt:
- Tibetha Santucci
- E-mail: tibetha.santucci@ahn.org
-
Ledende efterforsker:
- Kiran Sury, MD
-
-
Texas
-
Arlington, Texas, Forenede Stater, 76017
- Rekruttering
- Urology Partners of North Texas Research Institute
-
Ledende efterforsker:
- Keith Xavier, MD
-
Kontakt:
- Grace Yoon
- E-mail: gyoon@folioclinicalresearch.com
-
McAllen, Texas, Forenede Stater, 78504
- Rekruttering
- DHR Health Institute for Research and Development
-
Ledende efterforsker:
- Henry Ruiz, MD
-
Kontakt:
- Clarisa Medina
- E-mail: c.medina@dhrhealth.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Subject is a male of at least 50 years of age.
-
Subject demonstrates stress urinary incontinence.
-
Subject has undergone a radical prostatectomy, transurethral resection of the prostate, or other prostate surgery.
-
Subject is willing and able to undergo surgical implantation of ProACT devices.
-
Subject is willing and able to comply with study-required
follow-up activities, including annual telephonic follow -up interviews, for a period of 5 years from their date of initial implantation. This includes compliance even after possible explant of ProACT devices and/or possible implantation of subsequent therapies.
-
Subject is willing and able to sign the approved informed consent.
-
Subject has two positive 24-hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests).
-
Subject has a negative urine culture.
-
Subject has no known urogenital malignancy, other than previously treated prostate cancer.
-
Subject meets ONE of the following criteria:
- Baseline Prostate-Specific Antigen (PSA) of less than or equal to 2.5ng/mL;
- Baseline PSA > 2.5ng/mL and less than or equal to 10 ng/mL AND free PSA greater than or equal to 25% of total PSA;
-
Physician determines subject to be a suitable surgical candidate.
Exclusion Criteria:
- Subject has an existing urethral stricture, a history of any urethral strictures, or has ever had a urethrotomy.
- Subject has undergone prostate surgery or any anti-incontinence surgery within the last 12 months.
- Subject has an artificial urinary sphincter or any components of a previously implanted artificial urinary sphincter in vivo.
- Subject has undergone radiation therapy in the prostatic area within the last 12 months.
- Subject has untreated or unsuccessfully treated detrusor instability or over-activity.
- Subject has an atonic bladder.
- Subject had, presently has, or is suspected of having bladder cancer.
- Subject has untreated or unsuccessfully treated bladder stones.
- Subject has detrusor sphincter dyssynergia.
- Subject has known hemophilia or a bleeding disorder.
- Subject has a known severe contrast solution allergy (e.g., anaphylaxis, cardiac, or respiratory arrest).
- Subject has insulin-dependent diabetes that is uncontrolled or not controllable, as indicated by an A1c test result of = 6.5%.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: ProACT Adjustable Continence Therapy for Men
Patients implanted with ProACT Adjustable Continence Therapy for Men |
The ProACT therapy consists of two small, adjustable silicone balloons connected with tubing to a port. During a minimally invasive outpatient procedure, the balloons are surgically placed in the area where the prostate was removed or resected. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Urethral Strictures
Tidsramme: 5 years
|
Cumulative incidence of ProACT-related clinically relevant urethral strictures over 5 years of follow up. |
5 years
|
|
Device Erosions
Tidsramme: 5 years
|
Cumulative incidence of ProACT device erosions over 5 years of follow-up. |
5 years
|
|
Incontinence Quality of Life Questionnaire (I-QoL)
Tidsramme: 5 years
|
Results on Validated Incontinence Quality of Life Questionnaire |
5 years
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Effect of ProACT on Subsequent Stress Urinary Incontinence(SUI) Therapy
Tidsramme: 5 years
|
This data will be collected with a "Post ProACT Explant Subsequent Therapy Questionnaire". This questionnaire will ask 3 questions regarding the ProACT therapy
The scale for each question is 0-1. 0 Meaning no effect (a "No" response on the questionnaire) and 1 being some effect ("Yes" response on the questionnaire). No effect (0) on subsequent SUI therapies is the better outcome. |
5 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Philip Johnson, PhD, Uromedica, Inc. / Coloplast, Corp
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Mandlige urogenitale sygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Vandladningsforstyrrelser
- Nedre urinvejssymptomer
- Urologiske manifestationer
- Ufrivillig vandladning
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Urininkontinens, stress
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- PAS001
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .